6th Mar 2019 10:23
LONDON (Alliance News) - Akers Biosciences Inc on Wednesday said that, at a meeting held on Tuesday, its shareholders approved the company's delisting from AIM.
Akers shares were trading down 31% at 60.00 pence each on Wednesday.
The last day of dealings of the company's shares will be March 28, prior to being cancelled from the London Stock Exchange on March 29.
The AIM cancellation will have no effect on the company's Nasdaq Capital Market listing which will continue as usual.
The company has previously said the reason for its AIM delisting is due to the majority of trading in its shares occurring in the US. In 2017 and 2018, the company had added, over 99% of all trading in its shares occurred on the Nasdaq.